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Risk Factors for Mortality in Patients with Carbapenem-Resistant 
Acinetobacter baumannii Bacteremia: Impact of Appropriate 
Antimicrobial Therapy
This study investigated predictors associated with 14-day mortality, and focused especially 
on the impact of appropriate antimicrobial treatment among patients with carbapenem-
resistant Acinetobacter baumannii (CRAB) bacteremia. This retrospective study was 
performed at a tertiary care hospital in Korea from June 2007 to June 2010. Antibiotic 
therapy was considered appropriate if the antibiotics were administered via an appropriate 
route within 24 hr after the result of blood culture, had in vitro sensitivity to isolated strains, 
and of an adequate dosage according to the current guidelines. Ninety-five patients with 
A. baumannii bacteremia were included; of these, 53 (55.8%) were infected with CRAB. 
The overall infection-related 14-day mortality was higher in patients receiving inappropriate 
antimicrobial therapy than in patients receiving appropriate therapy (59.5% [22/37] vs 
13.8% [8/58], P < 0.05). Multivariate analysis showed that septic shock (OR 10.5, 95% CI, 
1.93-57.4; P = 0.006), carbapenem-resistance (OR 7.29, 95% CI 1.57-33.8; P = 0.01), 
pneumonia as a source of bacteremia (OR 5.29, 95% CI 1.07-26.1; P = 0.04), and 
inappropriate antimicrobial therapy (OR 8.05, 95% CI 1.65-39.2; P = 0.009) were 
independent risk factors for 14-day mortality. Early definite antimicrobial therapy had an 
influence on favorable outcomes in patients with A. baumannii bacteremia. 
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INTRODUCTION
Acinetobacter baumannii is an important nosocomial pathogen 
(1-6). Carbapenem is a preferred drug of choice for the treat-
ment of multidrug-resistant A. baumannii. However, carbape-
nem-resistant strains have now emerged around the world (2). 
Prevalence of carbapenem-resistant A. baumannii varies in dif-
ferent countries; in Korea, the resistance rate of A. baumannii 
against carbapenem was reported as 31.7% or 34.9% (7). 
  A. baumannii may cause various clinical manifestations rang-
ing from colonization to septic shock, and A. baumannii bacte-
remia-associated mortality rate is reported to be as high as 17%-
62% (8-10). Initiation of effective empirical antimicrobial treat-
ment might be important for reducing A. baumannii bactere-
mia-associated mortality. However, in Korea, initiation of broad 
spectrum antibiotic treatment with antibiotics such as carbap-
enem or colistin is difficult because of insurance problems (11, 
12). Because the severity of underlying disease could affect the 
outcomes in patients with A. baumannii bacteremia, it is not 
yet clear whether immediate and appropriate antimicrobial ther-
apy as proper dose and administration route can affect these 
outcomes (12, 13). Because of the presence of limited therapeu-
tic options for carbapenem-resistant A. baumannii (CRAB), it 
is important to understand the factors responsible for the devel-
opment of carbapenem-resistance and the risk factors associ-
ated with mortality. In this study, we investigated the factors   
associated with acquisition of CRAB in patients with A. bau-
mannii bacteremia; and the predictors associated with 14-day 
mortality. Our study especially focused on the impact of early 
and appropriate antimicrobial treatment after obtaining culture 
results. 
 
MATERIALS AND METHODS
Study design
A retrospective study was performed from June 2007 to June 
2010 at a tertiary care hospital with 1,200 beds in Korea. All pa-
tients over 16-yr old from whom A. baumannii was isolated from 
at least one set of blood cultures with definite clinical signs of 
infection were enrolled. Only the first bacteremic episode from 
each patient was included in this study. Antibiotic therapy was 
considered appropriate if the antibiotics administered via an 
appropriate route within 24 hr of blood culture results showed 
an in vitro effectiveness against isolated strains, and if the dos-Kim YJ, et al.  •  Carbapenem-Resistant Acinetobacter baumannii Bacteremia
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age was adequate according to the current guidelines. Infection 
was assessed according to “Centers for Disease Control and Pre-
vention” criteria, and patients were considered infected when 
A. baumannii was isolated from a sterile site in patients with 
definite clinical signs of infection (14). Prior antibiotics treat-
ment was defined as the use of systemic antibiotics for at least  
7 days within the preceding 28 days. For better understanding 
of the patients’ baseline status, we assessed the APACHE II score 
before bacteremia on the date of admission. We used 14-day in-
hospital mortality as the main outcome for assessment of mor-
tality for patients with serious conditions due to bacteremia. 
Microbiological examination
Identification of A. baumannii in blood samples was performed 
using a VITEK
R2 automated system (bioMérieux, Marcy l’Etoile, 
France). Susceptibility results were interpreted according to 
guidelines established by the Clinical and Laboratory Standards 
Institute (15). CRAB was defined as non-susceptible to merope-
nem and/or imipenem in vitro, and isolates with intermediate 
resistance were regarded as resistance.
Statistically analysis
Student’s t-test was used for analysis of continuous variables, 
and the chi-squared test or Fisher’s exact test was used for cate-
gorical variables and Student’s t test or the Mann-Whitney U 
test for continuous variables. We analyzed the risk factors asso-
ciated with mortality using univariate and multivariate logistic 
regression analyses. Survival curves were prepared using the 
Kaplan-Meier method with log-rank test. Statistical analysis was 
performed using SPSS 13.0 and a P value  < 0.05 was considered 
statistically significant.
Ethics statement
This study was approved by the institutional review board of 
Seoul St. Mary’s Hospital (Protocol No; KC10OISI0070). Informed 
consent was waived by the board. All the data collected during 
this study were kept confidential.
RESULTS
A total of 95 patients with A. baumannii bacteremia were in-
cluded in this study. Demographic characteristics of these pa-
Table 1. Clinical characteristics of patients with Acinetobacter baumannii bacteremia 
Parameters Total (n = 95) CRAB group (n = 53) Non-CRAB group (n = 42) P value
Age, mean ± SD (yr)   58.4 ± 20.9 59.4 ± 21.8   57.1 ± 19.9 0.59
Male sex 51 (53.7%) 33 (62.3%) 18 (42.9%) 0.06
Underlying disease
   Diabetes mellitus
   Hypertension
   Liver cirrhosis
   Transplant
   Malignancy
   Dialysis
   Immunosuppression
 
21 (22.1%)
21 (22.1%)
11 (11.6%)
7 (7.4%)
50 (52.6%)
16 (16.8%)
22 (23.2%)
 
16 (30.2%)
14 (26.4%)
  7 (13.2%)
  6 (11.3%)
28 (52.8%)
13 (24.5%)
14 (26.4%)
 
  5 (11.9%)
  7 (16.7%)
4 (9.5%)
1 (2.4%)
22 (52.4%)
3 (7.1%)
  8 (19.0%)
 
0.04
0.3
0.75
0.12
0.99
0.03
0.47
Previous surgery within one month 45 (47.4%) 25 (47.2%) 20 (47.6%) 0.96
Hospitalization in the preceding 90 days 43 (45.3%) 25 (47.2%) 18 (42.9%) 0.68
Invasive procedure
   Central venous catheter
   Surgical drainage
   Foley catheter
   Tracheostomy
   Mechanical ventilation
 
61 (64.2%)
31 (32.6%)
50 (52.6%)
13 (13.7%)
29 (30.5%)
 
37 (69.8%)
18 (34.0%)
34 (64.2%)
  9 (17.0%)
23 (43.4%)
 
24 (68.5%)
13 (30.9%)
16 (38.1%)
4 (9.5%)
  6 (14.3%)
 
0.28
0.8
0.02
0.31
0.003
The length of stay before bacteremia, mean ± SD    30.2 ± 51.5   30.0 ± 33.3   30.4 ± 68.3 0.96
APACHE II score 12.4 ± 7.3 14.4 ± 7.7 10.4 ± 6.1 0.005
Charlson’s weighted index of co-morbidity   2.7 ± 2.1   2.8 ± 1.9   2.5 ± 2.4 0.42
Prior antibiotics
   Cephalosporin
   Quinolone
   Aminoglycoside
   Carbapenem
 
44 (46.3%)
11 (11.6%)
7 (7.4%)
28 (29.5%)
 
17 (32.1%)
  6 (11.3%)
2 (3.8%)
26 (49.1%)
 
27 (64.3%)
  5 (11.9%)
  5 (11.9%)
2 (4.8%)
 
0.002
0.93
0.13
0.001
Source of bacteremia
   Pneumonia
   Urinary tract
   Vascular catheter-related
   Intra-abdomen
   Postoperative wound 
   Unknown
28 (29.5%)
6 (6.3%)
24 (25.3%)
15 (15.8%)
8 (8.4%)
8 (8.4%)
  
17 (32.1%)
2 (3.8%)
12 (22.6%)
  9 (17.0%)
  6 (11.3%)
1 (1.9%)
 
11 (26.2%)
4 (9.5%)
12 (28.6%)
  6 (14.3%)
2 (4.8%)
  7 (16.7%)
 
0.65
0.25
0.51
0.72
0.25
0.02
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tients are shown in Table 1. The mean age of the patients was 
58.4 ± 20.9 yr, and of the 95 patients, 53.7% were male. The mean 
length of stay before A. baumannii bacteremia was 30.2 ± 51.5 
days. The presumed sources of bacteremia were respiratory tract 
(n = 28, 29.5%), vascular catheter (n = 24, 25.3%), intra-abdomen 
(n = 15, 15.8%), postoperative wounds (n = 8, 8.4%), urinary tract 
(n = 6, 6.3%), and other unknown sources (n = 8, 8.4%). 
  Fifty-three patients (55.8%) were infected with CRAB. Univar-
iate analysis showed that the risk factors for acquisition of CRAB 
bacteremia were diabetes mellitus (OR 3.2, 95% CI 1.06-9.64; 
P = 0.04), dialysis (OR 4.23, 95% CI 1.11-15.9; P = 0.03) as an un-
derlying disease, use of foley catheter (OR 2.91, 95% CI 1.26-6.73; 
P = 0.01), mechanical ventilation support (OR 4.6, 95% CI 1.66-
12.77; P = 0.003), and prior use of cephalosporin (OR 3.81, 95% 
CI 1.62-8.96; P = 0.002) or carbapenem (OR 19.3, 95% CI 4.21-
87.9; P = 0.001). By multivariate analysis, diabetes mellitus as an 
underlying disease (OR 4.51, 95% CI 1.16-14.8; P = 0.03) and prior 
use of carbapenem (OR 14.8, 95% CI 2.76-79.5; P = 0.002) were 
independently associated with CRAB bacteremia (Table 2).
  The overall infection-related 14-day mortality in patients with 
A. baumannii bacteremia was 31.6% (30/95); infection-related 
14-day mortality was higher in patients receiving inappropriate 
antimicrobial therapy than in patients receiving appropriate 
therapy (59.5% [22/37] vs 13.8% [8/58], P < 0.05). The cumula-
tive survival curves of the patients according to the appropriate-
ness of antimicrobial therapy are shown in Fig. 1. Univariate anal-
ysis showed that the risk factors for infection-related 14-day mor-
tality in patients with A. baumannii bacteremia were central 
venous catheter (OR 4.02, 95% CI 1.37-11.83; P = 0.01), mechan-
ical ventilatoin (OR 5.77, 95% CI 2.22-15.02; P < 0.001), high 
APACHE II score (OR 4.01, 95% CI 1.39-11.4; P = 0.01), septic 
shock (OR 5.61, 95% CI 2.13-14.7; P < 0.001), carbapenem-resis-
tance (OR 9.14, 95% CI 2.86-29.2; P < 0.001), pneumonia as a 
source of bacteremia (OR 5.05, 95% CI 1.94-13.0; P < 0.001), and 
inappropriate antibiotic therapy (OR 6.58, 95% CI 2.53-17.1; P <  
0.001) (Table 3). Multivariate analysis showed that septic shock 
(OR 10.5, 95% CI 1.93-57.4; P = 0.006), carbapenem-resistance 
Table 2. Risk factors for acquisition of carbapenem resistant Acinetobacter baumannii bacteremia 
Risk factors
Univariate analysis Multivariate analysis
OR  95% CI P value OR  95% CI P value
Age, mean ± SD 1.0 0.99-1.02 0.59      
Male sex 2.2 0.96-5.02 0.06      
Underlying disease
   Diabetes mellitus
   Hypertension
   Liver cirrhosis
   Transplant
   Malignancy
   Dialysis
   Immunosuppression
  
3.2
1.79
1.44
5.23
1.01
4.23
1.53
  
1.06-9.64
0.65-4.95
0.39-5.31
0.61-45.3
0.45-2.29
1.11-15.9
0.57-4.10
  
0.04
0.3
0.56
0.12
0.95
0.03
0.40
 
4.51
 
 
 
 
1.48
 
 
1.16-14.8
 
 
 
 
0.27-7.7
 
 
0.03
 
 
 
 
0.66
 
Previous surgery within one month 1.01 0.45-2.29 0.96      
Hospitalization in the preceding 90 days 1.19 0.52-2.69 0.68      
Invasive procedure
   Central venous catheter
   Surgical drainage
   Foley catheter
   Tracheostomy
   Mechanical ventilation
 
1.74
1.14
2.91
1.94
4.6
 
0.74-4.10
0.48-2.73
1.26-6.73
0.54-6.81
1.66-12.77
 
0.21
0.76
0.01
0.31
0.003
 
 
 
2.51
 
2.75
 
 
 
0.89-7.59
 
0.77-9.62
 
 
 
0.08
 
0.12
The length of stay before bacteremia, mean ± SD  1 0.99-1.00 0.96       
Prior antibiotics
   Cephalosporin
   Quinolone
   Aminoglycoside
   Carbapenem
 
3.81
1.05
3.44
19.3
 
1.62-8.96
0.29-3.74
0.63-18.7
4.21-87.9
 
0.002
0.93
0.15
0.001
 
1.85
 
 
14.8
 
0.61-5.61
 
 
2.76-79.5
 
0.27
 
 
0.002
CRAB, carbapenem-resistant Acinetobacter baumannii.
Fig. 1. Survival curve according to the appropriateness of antimicrobial therapy.
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(OR 7.29, 95% CI 1.57-33.8; P = 0.01), pneumonia as a source of 
bacteremia (OR 5.29, 95% CI 1.07-26.1; P = 0.04), and inappro-
priate antimicrobial therapy (OR 8.05, 95% CI 1.65-39.2; P = 0.009) 
were the independent risk factors for 14-day mortality (Table 3). 
In sub-analysis of the CRAB group, patients receiving inappro-
priate antimicrobial therapy showed a higher mortality than 
those receiving appropriate therapy (67.9% [19/28] vs 28.0% [7/ 
25], P = 0.004). In the non-CRAB group, 33 patients received 
appropriate therapy and 97% of the patients had survived for 14 
days after the onset of bacteremia. 
DISCUSSION
A. baumannii is usually a healthcare-associated pathogen and 
is emerging as a cause of numerous global outbreaks (1, 2). An-
timicrobial resistance recently has emerged as an important 
problem. Carbapenem is widely used for the treatment of mul-
tidrug-resistant A. baumannii infections, however, reports of 
CRAB are also increasing worldwide. 
  Previous studies have showed that factors associated with mor-
tality in patients with A. baumannii infection are septic shock, 
age, severity of the underlying disease, and mechanical ventila-
tion (16-18). Delay in receiving empirical antimicrobial therapy 
has an adverse effect on clinical outcomes, however, some stud-
ies have shown that severity of illness is a more important factor 
for mortality than empirical therapy in hospital-acquired pneu-
monia caused by A. baumannii (12, 19). Moreover, in Korea, use 
of broad spectrum antibiotics prior to the isolation of multidrug-
resistant strains is limited.
  Our study revealed that independent risk factors associated 
with 14-day mortality in patients with A. baumannii bacteremia 
included septic shock, carbapenem-resistance, pneumonia as 
a source of bacteremia and inappropriate antibiotic therapy. This 
study evaluated the clinical outcomes in patients with A. bau-
mannii bacteremia according to the inappropriateness of anti-
biotics (i.e., antibiotics that were not active in vitro and those 
that were administered as an improper dose or through an im-
proper route) after obtaining the blood culture results. Our data 
suggest that early administration of appropriate antimicrobial 
therapy showed improved outcomes in patients with CRAB 
bacteremia, although underlying status played an important 
role in clinical outcome. 
  Studies have shown that APACHE II score is useful for the es-
timation of prognosis in Acinetobacter pneumonia (19, 20). In 
our study, a high APACHE II score was associated with mortali-
ty by univariate analysis; however this was not identified as an 
independent risk factor by multivariate analysis. This may be 
because of several reasons. First, some information, such as that 
on sepsis and mechanical ventilation, was not included while 
determining this score. Second, we assessed the APACHE II score 
before the occurrence of bacteremia on the date of admission, 
in order to best reflect the patients’ baseline status. Our study 
also showed that septic shock at the time of bacteremia was an 
independent risk factor for mortality. This finding suggested that 
a combination of other parameters, including the APACHE II 
score, is necessary for the evaluation of morbidity in patients 
with bacteremia. 
  The effect of antibiotic resistance on mortality is controversial. 
Some studies have reported that antibiotic resistance has an ad-
verse impact on the mortality rates in patients with A. baumannii 
bacteremia (1, 21). One study reported that mortality in patients 
with multidrug-resistant A. baumannii infection in surgical in-
tensive care units did not differ significantly from that in patients 
with non-multidrug-resistant A. baumannii infection. However, 
the study did not include patients who were simply bacteremic 
(6). Our results showed that carbapenem resistance was inde-
pendently associated with mortality. However, patients with 
CRAB bacteremia had a higher APACHE II score (14.4 ± 7.7 vs 
10.4 ± 6.1, P = 0.005) and received a more inappropriate antibi-
otic treatment (52.8% [28/53] vs 21.4% [9/42], P = 0.002) than 
those with non-CRAB bacteremia. CRAB bacteremia usually 
occurs in patients with severe illness and in patients with a high 
probability of receiving inappropriate antimicrobial therapy, 
which then negatively affect the outcomes. 
Table 3. Risk factors associated with 14-day mortality in patients with Acinetobacter baumannii bacteremia 
Risk factors
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Age ≥ 60 yr 1.48 0.61-3.6 0.38
Diabetes mellitus 2.45 0.90-6.66 0.07
Malignancy  1.72 0.72-4.13 0.21
Mechanical ventilator 5.77 2.22-15.0 < 0.001 1.59 0.39-6.41 0.51
Central venous catheter 4.02 1.37-11.8 0.01 3.53 0.68-18.2 0.13
APACHE II score ≥ 14 4.01 1.39-11.4 0.01 1.67 0.36-7.79 0.5
Septic shock 5.61 2.13-14.7 < 0.001 10.5 1.93-57.4 0.006
CR 9.14 2.86-29.2 < 0.001 7.29 1.57-33.8 0.01
Pneumonia as a source of bacteremia 5.05 1.94-13.0 0.001 5.29 1.07-26.1 0.04
Inappropriate antibiotic therapy 6.58 2.53-17.1 < 0.001 8.05 1.65-39.2 0.009
OR, odds ratio; CI, confidential interval; CR, carbapenem-resistance.Kim YJ, et al.  •  Carbapenem-Resistant Acinetobacter baumannii Bacteremia
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  Results from the present study also showed that factors for 
acquisition of CRAB included diabetes mellitus as an underlying 
disease and a prior exposure to carbapenem. Some studies have 
reported that prior use of carbapenem, third-generation cepha-
losporins and fluoroquinolones are independent risk factors 
for the acquisition of multidrug resistant A. baumannii (22, 23). 
Selective pressure exerted by use of broad spectrum antibiotics, 
such as carbapenem, leads to the emergence of multidrug-resis-
tant A. baumannii. Therefore, we consider multidrug resistance 
in patients with A. baumannii bacteremia who showed particu-
larly severe illness, and who had recently received carbapenem. 
In order to decrease acquisition of CRAB, judicious use of car-
bapenem is important. 
  Our study had some limitations, including the retrospective 
design, which was not randomized. A small number of patients 
were enrolled from a single center. Furthermore, we could not 
judge the appropriateness of the empirical antibiotic treatment 
in this study. It was rare that patients with CRAB bacteremia re-
ceived colistin empirically, because of insurance or restriction 
of broad spectrum antibiotics for policy of antibiotics control. 
However, our study should encourage clinicians not to delay 
definite antimicrobial treatment in patients with A. baumannii 
bacteremia.
  In conclusion, patients with A. baumannii bacteremia receiv-
ing early and appropriate antimicrobial therapy are expected to 
show favorable outcomes, although the status of underlying dis-
ease also plays an important role in the clinical outcomes. 
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